- Company
- Dong-A Forxiga loses the patent dispute
- by Kim, Jin-Gu Feb 7, 2023 05:48am
- A new method of avoiding material patents virtually fails the 'prodrug' strategy, which was drawing attention. Dong-A ST lost the Forxiga patent dispute alone. Dong-A ST pushed ahead with the release of Forxiga's late drug, Dapapro, on the basis of its victory in the first trial, but the ruling put considerable pressure on sales. ◆ Dong-A
- Company
- SGLT-2 Market ↑3x in 3 years
- by Jung, Sae-Im Feb 7, 2023 05:47am
- The domestic SGLT-2 inhibitor outpatient prescription market has grown to 170 billion won. It has more than tripled in the past three years. It has been about 10 years since SGLT-2 inhibitors entered Korea. This year, a major change is expected as a number of "Forxiga" generics leading the market are released and new domestic SGLT-2 inhibitor
- Company
- Does the Xospata dosing cycle limit disappear?
- by Eo, Yun-Ho Feb 6, 2023 05:51am
- The new leukemia drug Xospata is aiming to expand insurance benefit standards again. According to related industries, Astellas Pharmaceutical Korea submitted an application to expand the salary of Acute Myeloid Leukemia treatment Xospata at the end of last year and is currently discussing the schedule for the cancer disease review committee
- Company
- Mavyret occupies 85% of HCV market...sales fall 36% in 3 yrs
- by Kim, Jin-Gu Feb 6, 2023 05:51am
- Abbvie’s Mavyret has dominated the oral hepatitis C treatment market. Last year the drug increased its market share to 85%. Despite this increase in market share, the drug’s prescription performance fell 36% over the past 3 years. The analysis is that the absolute size of the Hepatitis C treatment market, which has a limited number of p
- Company
- EXKIVITY, PO lung cancer treatment, is released
- by Jung, Sae-Im Feb 3, 2023 08:51am
- Differences between oral medication and long-lasting effects "Further study needed to find suitable patient population" The second new drug targeting EGFR mutations, which are rare in non-small cell lung cancer, has been released in Korea. Takeda Pharmaceutical's Exkivity is expected to compete with oral drugs and long reaction duration. T
- Company
- Enhertu quickly lands at general hospitals in Korea
- by Eo, Yun-Ho Feb 3, 2023 05:53am
- Prescription of the next-generation new antibody-drug conjugate 'Enhertu' has started in earnest. According to industry sources, Enhertu (trastuzumab deruxtecan), AstraZeneca and Daiichi Sankyo Korea’s new antibody-drug conjugate drug for HER2-positive breast cancer have passed the drug committees (DCs) of 20 medical institutions in Kore
- Company
- Generic for Forxiga competition in the 90 Billion market
- by Kim, Jin-Gu Feb 3, 2023 05:53am
- The patent for "Forxiga," a large diabetes treatment that produces more than 90 billion won a year, was completely lifted by the Supreme Court ruling. It is expected that patent challengers will release Forxiga generic in two months. Competition for generics is expected to intensify when the sales ban period ends in January next year due to
- Company
- Hanmi’s Rolontis makes USD 10 million in 3 mths
- by Kim, Jin-Gu Feb 2, 2023 05:48am
- Hanmi Pharmaceutical’s partner Spectrum Pharmaceuticals issued a press release announcing that “’Rovedon (Korean brand name: Rolontis)’ that the company had launched in October last year made an estimated sales of KRW 10 million in 3 months.” Spectrum plans to release details of the results on Rolvedon in its Fiscal Year 2022 Earni
- Company
- Takeda's Exkivity launches as non-reimbursement
- by Eo, Yun-Ho Feb 1, 2023 05:52pm
- EGFR Exxon 20 insertion mutation target anticancer drug Exkivity, which is eaten by Takeda Pharmaceutical Korea, will be released as non-reimbursement in February. EGFR Exxon20 insertion mutation Non-small Cell Lung Cancer treatment Exkivity targets biomarkers such as Rybrevant of Janssen Korea, but there is a difference in that it is an oral
- Company
- JW Pharma develops new drugs with Merck Life Science
- by Lee, Seok-Jun Feb 1, 2023 05:55am
- JW Pharma is expanding AI technology from new drugs to raw drug research fields to increase R&D efficiency. JW Pharma announced on the 30th that it recently signed a business agreement with Merck Life Science in Germany to research and develop raw materials for new drugs using AI. Merck offers its AI software Synthia to JW Pharma. Synthia
